Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. (2015)

First Author: Bielack SS
Attributed to:  CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/jco.2014.60.0734

PubMed Identifier: 26033801

Publication URI: http://europepmc.org/abstract/MED/26033801

Type: Journal Article/Review

Volume: 33

Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Issue: 20

ISSN: 0732-183X